NZ752298A - Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x - Google Patents
Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor xInfo
- Publication number
- NZ752298A NZ752298A NZ752298A NZ75229817A NZ752298A NZ 752298 A NZ752298 A NZ 752298A NZ 752298 A NZ752298 A NZ 752298A NZ 75229817 A NZ75229817 A NZ 75229817A NZ 752298 A NZ752298 A NZ 752298A
- Authority
- NZ
- New Zealand
- Prior art keywords
- coagulation factor
- antibody
- administered
- weeks
- blood coagulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Disclosed is the use of a bispecific antibody that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X for the treatment of hemophilia A, acquired hemophilia A, von Willebrand disease or hemophilia A with emergence of an inhibitor against FVIII and/or FVIIIa, according to a given dosage regimen.
Claims (11)
1. [Claim 1] Use of a bispecific antibody that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X in the manufacture of a medicament for treating and/or reducing the incidence of a disease that develops and/or progresses due to a decrease or deficiency in the activity of blood coagulation factor VIII (FVIII) and/or activated blood coagulation factor VIII (FVIIIa), wherein the bispecific antibody is to be administered subcutaneously to a subject at a weekly loading dose of 3 mg/kg of the antibody for four weeks; and, after the loading dose administrations are complete, a maintenance dose of the antibody is to be subcutaneously administered to the subject one or more times, wherein the maintenance dose is 6 mg/kg of the antibody that is to be administered to the subject every four weeks in a single dose or multiple divided doses, wherein the maintenance dose is to be administered (i) in one single dose at 6 mg/kg of the antibody every four weeks; or (ii) in two single doses each at 3 mg/kg of the antibody every four weeks, wherein one single dose of the maintenance dose at 3 mg/kg of the antibody is administered once every two weeks, wherein the disease is hemophilia A, acquired hemophilia A, von Willebrand disease, or hemophilia A with emergence of an inhibitor against FVIII and/or FVIIIa and wherein the bispecific antibody (A) comprises a first polypeptide which is an H chain containing an H chain variable region amino acid sequence of SEQ ID NO: 4; a second polypeptide which is an H chain containing an H chain variable region amino acid sequence of SEQ ID NO: 9; and a third and fourth polypeptide which are a commonly shared L chain containing an L chain variable region amino acid sequence of SEQ ID NO: 14; or (B) comprises a first polypeptide which is an H chain containing the amino acid sequence of SEQ ID NO: 5; a second polypeptide which is an H chain containing the amino acid sequence of SEQ ID NO: 10; and a third and fourth polypeptide which are a commonly shared L chain containing the amino acid sequence of SEQ ID NO: 15.
2. [Claim 2] The use of claim 1, wherein the bispecific antibody is emicizumab.
3. [Claim 3] The use of claim 1, wherein the maintenance dose is to be administered in one single dose at 6 mg/kg of the antibody every four weeks.
4. [Claim 4] The use of claim 1, wherein the maintenance dose is to be administered in two single doses of the antibody each at 3 mg/kg of the antibody every four weeks, wherein one single dose at 3 mg/kg of the antibody is to be administered once every two weeks.
5. [Claim 5] The use of claim 1, wherein the maintenance doses are to be administered to the subject over multiple four-week periods.
6. [Claim 6] The use of claim 1, wherein the disease is hemophilia A.
7. [Claim 7] The use of claim 1, wherein the disease is acquired hemophilia A.
8. [Claim 8] The use of claim 1, wherein the disease is von Willebrand disease.
9. [Claim 9] The use of claim 1, wherein the disease is hemophilia A with emergence of an inhibitor against blood coagulation factor VIII and/or activated blood coagulation factor VIII.
10. [Claim 10] The use of claim 1, wherein the maintenance doses are to be administered until at least 52 weeks have elapsed after the first loading dose was administered.
11. [Claim 11] The use of any one of claims 1 to 10, substantially as herein described, with reference to any example thereof and with reference to the appended figures.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383933P | 2016-09-06 | 2016-09-06 | |
| US201662437281P | 2016-12-21 | 2016-12-21 | |
| US201762485514P | 2017-04-14 | 2017-04-14 | |
| PCT/JP2017/031933 WO2018047813A1 (en) | 2016-09-06 | 2017-09-05 | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ752298A true NZ752298A (en) | 2025-02-28 |
| NZ752298B2 NZ752298B2 (en) | 2025-06-04 |
Family
ID=
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017101705A (en) | PHARMACEUTICAL COMPOSITION INTENDED FOR APPLICATION FOR PREVENTION AND / OR TREATMENT OF A DISEASE THAT IS DEVELOPING OR PROGRESSING AS A RESULT OF REDUCTION OR LOSS OF SURVIVAL FACTOR | |
| RU2019109464A (en) | METHODS OF APPLICATION OF A BISPECIFIC ANTIBODY THAT RECOGNIZES COAGULATION FACTOR IX AND / OR ACTIVATED COAGULATION FACTOR IX AND COAGULATION FACTOR X AND / OR ACTIVATED COAGULATION FACTOR X | |
| WO2021050953A8 (en) | Compositions and methods for the delivery of therapeutic biologics for treatment of disease | |
| FI3793588T3 (en) | Methods of treating hemophilia a | |
| NZ744233A (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
| FI3227675T3 (en) | Activin-actrii antagonists and uses for treating myelodysplastic syndrome | |
| RU2016151757A (en) | PDL-1 AND PD-1 ANTAGONISTS FOR TREATMENT OF HPV-NEGATIVE CANCER FORMS | |
| JP2016514132A5 (en) | ||
| IL292193B2 (en) | Anti-B7-H1 antibodies for the treatment of tumors | |
| JP2018509388A5 (en) | ||
| JP2019501886A5 (en) | ||
| JP2016516073A5 (en) | ||
| RU2014100107A (en) | TREATMENT OF BLOOD COAGULATION DISORDERS BY INTRODUCING RECOMBINANT EF | |
| EP3062809B1 (en) | A cxcr4 peptide inhibitor for use in treating acute myeloid leukemia with a flt3 mutation | |
| WO2020047352A8 (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
| EP4424366A3 (en) | Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf | |
| ZA202106768B (en) | Triamterene or nolatrexed for use in the treatment of phenylketonuria | |
| JOP20190019A1 (en) | PHARMACEUTICAL COMPOSITION FOR TREATING GROWTH HORMONE DEFICIENCY CONTAINING hGH FUSION PROTEIN | |
| MX2021009114A (en) | Methods of prophylactic treatment using recombinant vwf (rvwf). | |
| WO2020243273A3 (en) | Methods of treating cholangiocarcinoma | |
| NZ752298B2 (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
| JP2018522881A5 (en) | ||
| RU2018132694A (en) | PHARMACEUTICAL COMPOSITION, INCLUDING RECOMBINANT HUMAN GROWTH HORMONE FOR TREATMENT OF GROWTH HORMONE DEFICIENCY | |
| BR112021018219A2 (en) | Method of treatment of infective endocarditis | |
| AR099907A1 (en) | PHARMACEUTICAL COMPOSITION USED IN THE PREVENTION AND / OR TREATMENT OF DISEASES CAUSED AND / OR AGGRAVATED BY A DECREASE OR DEFICIENCY OF THE ACTIVITY OF THE BLOOD COAGULATION FACTOR VIII AND / OR THE ACTIVATED BLOOD COAGULATION FACTOR VIII |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 SEP 2026 BY DENNEMEYER + CO. SARL Effective date: 20250826 |